Drugs / Trevogrumab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02943239 | Dec 2016 → Apr 2019 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02741739 | Mar → Apr 2016 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01910220 | Aug 2013 → Jun 2014 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01720576 | Oct 2012 → Jun 2013 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01507402 | Jan → Nov 2012 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT06299098 | Mar 2024 → Jun 2026 overdue | obesity disorder | Regeneron Pharmaceuticals | Active not recruiting | Met primary |
| Phase 2 | NCT03710941 | Feb 2019 → Aug 2020 | inclusion body myositis | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01963598 | Nov 2013 → Jan 2015 | muscular atrophy | Regeneron Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Regeneron Pharmaceuticals | Results Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss regeneron.com ↗
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment |
| 2025-09-17 | Regeneron Pharmaceuticals | Results Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD regeneron.com ↗
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss |
| 2025-08-01 | Regeneron Pharmaceuticals | Results Regeneron Reports Second Quarter 2025 Financial and Operating Results regeneron.com ↗
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab preserved lean mass while increasing loss of fat mass. |
| 2025-06-02 | Regeneron Pharmaceuticals | Results Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass regeneron.com ↗
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Regeneron Pharmaceuticals | Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss regeneron.com ↗ |
| 2025-09-17 | Regeneron Pharmaceuticals | Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD regeneron.com ↗ |
| 2025-08-01 | Regeneron Pharmaceuticals | Regeneron Reports Second Quarter 2025 Financial and Operating Results regeneron.com ↗ |
| 2025-06-02 | Regeneron Pharmaceuticals | Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass regeneron.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trevogrumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299098 ↗ |
| Known as | Human igg4 anti-myostatin mab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545374 ↗ |
| Known as | REGN1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02943239 ↗ |
| Known as | SAR391786 | “This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of Intravenous (IV) and Subcutaneous (SC)...” NCT01507402 ↗3“This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in...” NCT01963598 ↗ “subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.” NCT01720576 ↗ “Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)” NCT01910220 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL3545374 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3545374 ↗ |
| Route | Intravenous | “Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786)” NCT01507402 ↗ |
| Route | Subcutaneous | “Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786)” NCT01507402 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL3545374 ↗ |